Peringatan Keamanan

LD50=350mg/kg (orally in mice)

Dacarbazine

DB00851

small molecule approved investigational

Deskripsi

An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

Struktur Molekul 2D

Berat 182.187
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 5 hours
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Erratic, slow and incomplete.

Metabolisme

Hepatic

Rute Eliminasi

Dacarbazine is subject to renal tubular secretion rather than glomerular filtration. In man, dacarbazine is extensively degraded. Besides unchanged dacarbazine, 5-aminoimidazole -4 carboxamide (AIC) is a major metabolite of dacarbazine excreted in the urine.

Interaksi Makanan

1 Data
  • 1. Take on an empty stomach. Fasting for four to six hours before treatment may be beneficial to reduce nausea and vomiting associated with Dacarbazine therapy.

Interaksi Obat

1355 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Dacarbazine.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Dacarbazine.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Dacarbazine.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Dacarbazine.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Dacarbazine.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Dacarbazine.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dacarbazine.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Dacarbazine.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Dacarbazine.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Dacarbazine.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Dacarbazine.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Dacarbazine.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Dacarbazine.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Dacarbazine.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Dacarbazine.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Dacarbazine.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Dacarbazine.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Dacarbazine.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Dacarbazine.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Dacarbazine.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Dacarbazine.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Dacarbazine.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Dacarbazine.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Dacarbazine.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Dacarbazine.
Cladribine Dacarbazine may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Dacarbazine.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Dacarbazine.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Dacarbazine.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Dacarbazine.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Dacarbazine.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Dacarbazine.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Dacarbazine.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Dacarbazine.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Dacarbazine.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Dacarbazine.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Dacarbazine.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Dacarbazine.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Dacarbazine.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Dacarbazine.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Dacarbazine.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Dacarbazine.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Dacarbazine.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Dacarbazine.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Dacarbazine.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Dacarbazine.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Dacarbazine.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Dacarbazine.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Dacarbazine.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Dacarbazine.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Dacarbazine.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Dacarbazine.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Dacarbazine.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Dacarbazine.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Dacarbazine.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Dacarbazine.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Dacarbazine.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Dacarbazine.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Dacarbazine.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Dacarbazine.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Dacarbazine.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Dacarbazine.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Dacarbazine.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Dacarbazine.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Dacarbazine.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Dacarbazine.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Dacarbazine.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Dacarbazine.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Dacarbazine.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Dacarbazine.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Dacarbazine.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Dacarbazine.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Dacarbazine.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Dacarbazine is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Penicillamine.
Prednisolone The risk or severity of adverse effects can be increased when Dacarbazine is combined with Prednisolone.
Sirolimus The risk or severity of adverse effects can be increased when Dacarbazine is combined with Sirolimus.
Mechlorethamine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Dacarbazine is combined with Carboplatin.
Methylprednisolone The risk or severity of adverse effects can be increased when Dacarbazine is combined with Methylprednisolone.
Dactinomycin The risk or severity of adverse effects can be increased when Dacarbazine is combined with Dactinomycin.
Cytarabine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Cytarabine.
Azathioprine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Azathioprine.
Doxorubicin The risk or severity of adverse effects can be increased when Dacarbazine is combined with Doxorubicin.
Hydroxyurea The risk or severity of adverse effects can be increased when Dacarbazine is combined with Hydroxyurea.
Busulfan The risk or severity of adverse effects can be increased when Dacarbazine is combined with Busulfan.
Mycophenolic acid The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mycophenolic acid.
Topotecan The risk or severity of adverse effects can be increased when Dacarbazine is combined with Topotecan.
Mercaptopurine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Dacarbazine is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Dacarbazine is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Capecitabine.
Trilostane The risk or severity of adverse effects can be increased when Dacarbazine is combined with Trilostane.
Procarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Dacarbazine is combined with Arsenic trioxide.

Target Protein

DNA
DNA polymerase alpha subunit B POLA2
6-phosphogluconate dehydrogenase, decarboxylating PGD

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 11 • International brands: 6
Produk
  • Dacarbazine
    Injection, powder, lyophilized, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, lyophilized, for solution • 200 mg/20mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, for solution • 200 mg/20mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, lyophilized, for solution • 10 mg/1mL • Intravenous • US • Generic • Approved
  • Dacarbazine
    Injection, powder, for solution • 200 mg/20mL • Intravenous • US • Generic • Approved
Menampilkan 8 dari 11 produk.
International Brands
  • Dacatic — Orion Corporation
  • Déticène — Sanofi-Aventis
  • Deticene — Sanofi-Aventis
  • Detimedac — medac GmbH
  • DTIC — Bayer AG
  • DTIC-Dome — Bayer Schering

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul